Jim Cramer dampens some of the excitement surrounding Arena (ARNA -4.1%), saying that the...

|About: Arena Pharmaceuticals, Inc. (ARNA)|By:, SA News Editor

Jim Cramer dampens some of the excitement surrounding Arena (ARNA -4.1%), saying that the company's Belviq diet drug won't make as much money as people think. Cramer notes that Arena will receive just 40% of the revenues from treatment, which is anyway not as effective as initially thought, nor as good as Vivus' (VVUS) yet-to-be-approved Qnexa.